Modified Gene Delivery Vector Targeting for Precision Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing technologies face limitations in precision, efficiency, and delivery mechanisms, particularly in complex organisms, leading to incomplete or inaccurate editing and challenges in addressing polygenic disorders.
Innovation Solution
A method for gene editing using a modified gene delivery vector with a targeting agent to direct the gene editing agent to specific cells or tissues, utilizing CRISPR-Cas9 or Zinc Finger Nucleases, and incorporating stability enhancers to ensure precise and efficient genetic modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing gene therapy delivery mechanisms are used, then gene editing can be performed, but delivery efficiency is low and targeting precision is insufficient
Solution Approach 1:
The patent introduces a modified gene delivery vector as an intermediary carrier that bridges the gap between gene editing agents and target cells. This vector is engineered with specific properties to overcome the limitations of direct delivery methods, achieving both high delivery efficiency and precise targeting simultaneously
Solution Approach 2:
The patent modifies key parameters of the delivery system including the vector structure, surface properties, and biological activity characteristics. These parameter changes enable the delivery mechanism to achieve optimal balance between efficiency and precision for gene editing applications
2Measurement precision
If gene delivery vectors are modified with targeting agents, then targeting precision improves, but device complexity increases
Solution Approach 1:
The patent divides the gene delivery system into distinct functional modules: the base vector structure, the targeting agent component, and the gene editing payload. This segmentation allows independent optimization of each component and simplifies the overall modification process while maintaining high targeting precision
3Reliability
If stability enhancers are incorporated into the delivery vector, then gene editing reliability improves, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates stability enhancers during the vector manufacturing process rather than adding them later. This preliminary action ensures consistent stability characteristics in the final product while streamlining the manufacturing workflow and reducing additional processing steps
Data Source
AI summary
The present disclosure relates to a method (100, 200) for gene editing of a cell or tissue. The method (100,200) includes introducing a gene editing agent into the cell or tissue using a gene delivery vector. The method (100,200) also includes modifying the gene delivery vector with a targeting agent to direct the gene editing agent to the desired cell or tissue. The method (100,200) also includes attuning the gene delivery agent to modify or replace the mutated gene. The method (100,200) also includes introducing other genetic modifications through the genetic agent. The method (100,200) also includes modifying the gene delivery vector with agents to enhance the stability or activity of the gene editing agent.